Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Schierwagen, Robert ^a   Maybüchen, Lara ^a   Zimmer, Sebastian ^a   Hittatiya, Kanishka ^a   Bäck, Christer ^b   Klein, Sabine ^a   Uschner, Frank E ^a   Reul, Winfried ^a   Boor, Peter ^b   Nickenig, Georg ^a   Strassburg, Christian P ^a   Trautwein, Christian ^b   Plat, Jogchum ^c   Lütjohann, Dieter ^a   Sauerbruch, Tilman ^a   Tacke, Frank ^b   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADVERSE EFFECTS; ANIMAL; GENETICS; HYPERTENSION, PORTAL; KIDNEY; KNOCKOUT MOUSE; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MOUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; WESTERN DIET;

ANIMALS; APOLIPOPROTEINS E; DIET, WESTERN; HYPERTENSION, PORTAL; KIDNEY; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84939172436     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12931     Document Type: Article

References (52)

1. Tiniakos, D. G., Vos, M. B. & Brunt, E. M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5, 145-171 (2010).
2. Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844-1850 (2001).
3. Sanyal, A. J. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192 (2001).
4. Sanyal, A. J. et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682-689 (2006).
5. Day, C. P. & James, O. F. Steatohepatitis: a tale of two 'hits'?. Gastroenterology 114, 842-845 (1998).
6. Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 (2010).
7. Marí, M. et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 4, 185-198 (2006).
8. Matsuzawa, N. et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46, 1392-1403 (2007).
9. Cassiman, D. & Jaeken, J. NASH may be trash. Gut 57, 141-144 (2008).
10. Liedtke, C. et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis & Tissue Repair 6, 19 (2013).
11. Takahashi, Y., Soejima, Y. & Fukusato, T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18, 2300-2308 (2012).
12. Reddick, R. L., Zhang, S. H. & Maeda, N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14, 141-147 (1994).
13. Song, G. et al. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Lipids Health Dis 10, 8 (2011).
14. Ferré, N. et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G553-562 (2009).
15. King, V. L. et al. A Murine Model of Obesity With Accelerated Atherosclerosis. Obesity 18, 35-41 (2010).
16. Martínez-Clemente, M. et al. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology 52, 1980-1991 (2010).
17. Martínez-Clemente, M. et al. 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 51, 817-827 (2010).
18. Kampschulte, M. et al. Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis. Lab. Invest. 94, 1273-1282 (2014).
19. Leclercq, I. A., Farrell, G. C., Schriemer, R. & Robertson, G. R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 37, 206-213 (2002).
20. Nakayama, H. et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 56, 470-475 (2007).
21. Larter, C. Z., Yeh, M. M., Williams, J., Bell-Anderson, K. S. & Farrell, G. C. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. Journal of Hepatology 49, 407-416 (2008).
22. Kawasaki, T. et al. Rats Fed Fructose-Enriched Diets Have Characteristics of Nonalcoholic Hepatic Steatosis. J. Nutr. 139, 2067-2071 (2009).
23. Simon, Y. et al. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis. World J Gastroenterol 20, 17839-17850 (2014).
24. Caballero, F. et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. Journal of Hepatology 50, 789-796 (2009).
25. Simonen, M. et al. Desmosterol in human nonalcoholic steatohepatitis. Hepatology 58, 976-982 (2013).
26. Yang, S. Q., Lin, H. Z., Lane, M. D., Clemens, M. & Diehl, A. M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. USA 94, 2557-2562 (1997).
27. Ito, M. et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol. Res. 37, 50-57 (2007).
28. Van Rooyen, D. M. et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J. Hepatol. 59, 144-152 (2013).
29. Bieghs, V. et al. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS ONE 7, e30668 (2012).
30. Kohli, R. et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52, 934-944 (2010).
31. Charlton, M. et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G825-834 (2011).
32. Wouters, K. et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486 (2008).
33. Francque, S. et al. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol 22, 1449-1457 (2010).
34. Itoh, M. et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am. J. Pathol. 179, 2454-2463 (2011).
35. Wolf, M. J. et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26, 549-564 (2014).
36. Tiyerili, V. et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res. Cardiol. 105, 465-477 (2010).
37. Hoyer, F. F. et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell. Cardiol. 51, 1007-1014 (2011).
38. Baeck, C. et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426 (2012).
39. Klein, S. et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. Journal of Hepatology 57, 1220-1227 (2012).
40. Trebicka, J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242-253 (2007).
41. Trebicka, J. et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47, 1264-1276 (2008).
42. Trebicka, J. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol. 53, 702-712 (2010).
43. Trebicka, J. et al. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 50, 1924-1935 (2009).
44. Trebicka, J. et al. Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver Int. 31, 860-870 (2011).
45. Von Meyenn, F. et al. Glucagon-Induced Acetylation of Foxa2 Regulates Hepatic Lipid Metabolism. Cell Metabolism 17, 436-447 (2013).
46. Parathath, S. et al. Diabetes Adversely Affects Macrophages During Atherosclerotic Plaque Regression in Mice. Diabetes 60, 1759-1769 (2011).
47. Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696-699 (1995).
48. Huss, S. et al. Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis. Fibrogenesis Tissue Repair 3, 10 (2010).
49. Boor, P. et al. The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int. 80, 1182-1197 (2011).
50. Lütjohann, D. et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J. Lipid Res. 43, 1078-1085 (2002).
51. Thelen, K. M. et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316, 1146-1152 (2006).
52. Dullens, S. P. J., Mensink, R. P., Bragt, M. C. E., Kies, A. K. & Plat, J. Effects of emulsified policosanols with different chain lengths on cholesterol metabolism in heterozygous LDL receptor-deficient mice. J. Lipid Res. 49, 790-796 (2008).